Chemoimmunotherapy of murine bladder cancer

B. J. Stogdill, D. L. Lamm, Robert B Livingston

Research output: Contribution to journalArticle

Abstract

The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.

Original languageEnglish (US)
Pages (from-to)179-181
Number of pages3
JournalInvestigative Urology
Volume19
Issue number3
StatePublished - 1981
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Cyclophosphamide
Methotrexate
Mycobacterium bovis
Neoplasms
Inbred C3H Mouse
Transitional Cell Carcinoma
Poisons
Combination Drug Therapy
Immunotherapy
Cisplatin
Appointments and Schedules
Observation
Drug Therapy
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stogdill, B. J., Lamm, D. L., & Livingston, R. B. (1981). Chemoimmunotherapy of murine bladder cancer. Investigative Urology, 19(3), 179-181.

Chemoimmunotherapy of murine bladder cancer. / Stogdill, B. J.; Lamm, D. L.; Livingston, Robert B.

In: Investigative Urology, Vol. 19, No. 3, 1981, p. 179-181.

Research output: Contribution to journalArticle

Stogdill, BJ, Lamm, DL & Livingston, RB 1981, 'Chemoimmunotherapy of murine bladder cancer', Investigative Urology, vol. 19, no. 3, pp. 179-181.
Stogdill, B. J. ; Lamm, D. L. ; Livingston, Robert B. / Chemoimmunotherapy of murine bladder cancer. In: Investigative Urology. 1981 ; Vol. 19, No. 3. pp. 179-181.
@article{cb86d25876894f999a19864c250bfe03,
title = "Chemoimmunotherapy of murine bladder cancer",
abstract = "The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.",
author = "Stogdill, {B. J.} and Lamm, {D. L.} and Livingston, {Robert B}",
year = "1981",
language = "English (US)",
volume = "19",
pages = "179--181",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Chemoimmunotherapy of murine bladder cancer

AU - Stogdill, B. J.

AU - Lamm, D. L.

AU - Livingston, Robert B

PY - 1981

Y1 - 1981

N2 - The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.

AB - The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.

UR - http://www.scopus.com/inward/record.url?scp=0019789034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019789034&partnerID=8YFLogxK

M3 - Article

C2 - 7298287

AN - SCOPUS:0019789034

VL - 19

SP - 179

EP - 181

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -